This listing of the claims will replace all prior versions and listings of claims in the application:

Listing of Claims:

Claim 1 (previously presented): A compound of Formula I:



wherein

R^1, R^2, R^3 and R^4 are independently

H,

HO,

$R^{13}O$-,

$R^{13}S$-,

halogen,

C1-C3-alkyl,

CF_3,

$R^{14}CO_2$-,

$R^{14}O_2C$-,

$R^{14}CO$-

$R^{14}CONH$-,

$R^{14}NHCO-$,

$R^{14}NHCO_2-$,

$R^{14}OCONH-$,

$R^{14}O_2S-$,

$R^{14}OS-$, or

$R^{15}R^{16}N-$; or

R^1 and R^2, or R^2 and R^3, or R^3 and R^4 taken together can be

$-SCH_2S-$,

$-SCH_2O-$,

$-OCH_2S-$,

$-SCH_2CH_2S-$,

$-SCH_2CH_2O-$, or

$-OCH_2CH_2S-$;

wherein one of R^1, R^3 and R^4 must be C1-C3-alkoxy or C1-C3-alkylthio group;

R^5, R^6, R^7 and R^8 are independently

H,

C1-C6-alkyl,

C3-C6-alkenyl,

C3-C6-cycloalkyl,

phenyl or substituted phenyl, wherein the phenyl is substituted with one or two substituents, C1-C3-alkyl, halogen, $R^{13}O-$, CF_3-, $R^{14}O_2S-$, $R^{14}OS-$, $R^{14}CO-$, $R^{14}CO_2-$, $R^{14}O_2C-$, $R^{14}CONH-$, $R^{14}NHCO-$; or

R^5 and R^6 taken together can be C3-C6-cycloalkyl;

R^7 and R^8 taken together can be C3-C6-cycloalkyl;

R^9 is

$R^{15}R^{16}NCO-$,

$R^{15}R^{16}NCS-$,

$R^{17}OCO-$,

$R^{15}CO-$,

$R^{15}R^{16}NCH_2CO-$,

$R^{14}O_2C-(CH_2)_n-$,

$R^{15}R^{16}NCO-(CH_2)_n-$,

$NC-(CH_2)_n-$,

H,

C1-C6-alkyl,

C3-C6-alkenyl, or

C3-C6-cycloalkyl; or

R^8 and R^9 taken together can be

$-(CH_2)_mCH_2(R^{15})NCO-$,

$-(CH_2)_mCH_2OCO-$, or

$-(CH_2)_mCH_2CH_2CO-$;

R^{10} and R^{11} are independently

H,

$R^{15}R^{16}N-$,

$R^{14}HNCO-$, or

$R^{14}CONH-$;

R^{12} is

H,

halogen,

HO,

$R^{13}O-$,

$R^{15}R^{16}N-$,

C1-C3-alkyl,

CF_3,

$R^{14}CO_2-$,

$R^{14}CO-$, or

$R^{14}CONH$-;

R^{13} is C1-C3-alkyl;

R^{14} is H or C1-C3-alkyl;

R^{15} and R^{16} are independently

H,

C1-C10-alkyl,

C1-C6-perfluoroalkyl,

C3-C10-alkenyl, or

C3-C6-cycloalkyl; or

R^{15} and R^{16} taken together can be C3-C6-cycloalkyl;

R^{17} is C1-C6-alkyl, C3-C6-alkenyl, or C3-C6-cycloalkyl;

n is 1 to 6;

m is 0 to 2;

and pharmaceutically acceptable salts thereof;

wherein R^{10} and R^{11} cannot be both H.

Claim 2 (previously presented): The compound of claim 1 of Formula I wherein one of the substituents of R^1, R^3 and R^4 must be Cl—C3—alkylthio group or Cl—C3—alkoxy group, the other substituents are independently H, $R^{13}O$-, $R^{13}S$-, halogen, or C1-C3-alkyl;

R^2 and R^3 taken together can be $-SCH_2S-$, SCH_2O-, or $-OCH_2S-$;

R^9 is

$R^{15}R^{16}NCO$-,

$R^{15}R^{16}NCS$-,

$R^{17}OCO$-,

$R^{15}CO$-, or

H;

R^{10} and R^{11} are independently H, H_2N-, or CH_3CONH-;
and pharmaceutically acceptable salts thereof.

Claim 3 (previously presented): A composition comprising the compound of claim 2 and a pharmaceutically acceptable carrier.

Claims 4-7 (canceled).

Claim 8 (previously presented): A composition comprising the compound of claim 1 and a pharmaceutically acceptable carrier.

Claim 9 (canceled).

Claim 10 (currently amended): A method for treating a patient suffering from ischemia, epilepsy or stroke, the method comprising administering to the patient, in an effective amount to alleviate the symptoms of the ischemia, epilepsy or stroke, a compound of Formula I:



wherein

R^1, R^2, R^3 and R^4 are independently

H,

HO,

$R^{13}O$-,

$R^{13}S$-,

halogen,

C1-C3-alkyl,

CF_3,

$R^{14}CO_2$-,

$R^{14}O_2C$-,

$R^{14}CO$-,

$R^{14}CONH$-,

$R^{14}NHCO$-,

$R^{14}NHCO_2$-,

$R^{14}OCONH$-,

$R^{14}O_2S$-,

$R^{14}OS$-, or

$R^{15}R^{16}N$-; or

R^1 and R^2, or R^2 and R^3, or R^3 and R^4 taken together can be

$-SCH_2S-$,

$-SCH_2O-$,

$-OCH_2S-$,

$-SCH_2CH_2S-$,

$-SCH_2CH_2O-$, or

$-OCH_2CH_2S-$;

wherein one of R^1, R^3 and R^4 must be C1-C3-alkoxy or C1-C3-alkylthio group;

R^5, R^6, R^7 and R^8 are independently

H,

C1-C6-alkyl,

C3-C6-alkenyl,

C3-C6-cycloalkyl,

phenyl or substituted phenyl, wherein the phenyl is substituted with one or two substituents, C1-C3-alkyl, halogen, $R^{13}O$-, CF_3-, $R^{14}O_2S$-, $R^{14}OS$-, $R^{14}CO$-, $R^{14}CO_2$-, $R^{14}O_2C$-, $R^{14}CONH$-, $R^{14}NHCO$-; or

R^5 and R^6 taken together can be C3-C6-cycloalkyl;

R^7 and R^8 taken together can be C3-C6-cycloalkyl;

R^9 is

$R^{15}R^{16}NCO$-,

$R^{15}R^{16}NCS$-,

$R^{17}OCO$-,

$R^{15}CO$-,

$R^{15}R^{16}NCH_2CO$-,

$R^{14}O_2C-(CH_2)_n$-,

$R^{15}R^{16}NCO-(CH_2)_n$-,

$NC-(CH_2)_n$-,

H,

C1-C6-alkyl,

C3-C6-alkenyl, or

C3-C6-cycloalkyl; or

R^8 and R^9 taken together can be

$-(CH_2)_mCH_2(R^{15})NCO$-,

$-(CH_2)_mCH_2OCO$-, or

$-(CH_2)_mCH_2CH_2CO-[,]$;

R^{10} and R^{11} are independently

H,

$R^{15}R^{16}N$-,

$R^{14}HNCO-$, or

$R^{14}CONH-$;

R^{12} is

H,

halogen,

HO,

$R^{13}O-$,

$R^{15}R^{16}N-$,

C1-C3-alkyl,

CF_3,

$R^{14}CO_2-$,

$R^{14}CO-$, or

$R^{14}CONH-$;

R^{13} is C1-C3-alkyl;

R^{14} is H or C1-C3-alkyl;

R^{15} and R^{16} are independently

H,

C1-C10-alkyl,

C1-C6-perfluoroalkyl,

C3-C10-alkenyl, or

C3-C6-cycloalkyl; or

R^{15} and R^{16} taken together can be C3-C6-cycloalkyl;

R^{17} is C1-C6-alkyl, C3-C6-alkenyl, or C3-C6-cycloalkyl;

n is 1 to 6;

m is 0 to 2;

and pharmaceutically acceptable salts thereof;

wherein R^{10} and R^{11} cannot be both H,

in combination with a pharmaceutically acceptable carrier.

Claim 11 (previously presented): The method of claim 10 wherein, in the compound of Formula I,

one of the substituents of R^1, R^3 and R^4 must be C1-C3-alkylthio group or C1-C3-alkoxy group, the other substituents are independently H, $R^{13}O$-, $R^{13}S$-, halogen, or C1-C3-alkyl;

R^2 and R^3 taken together can be $-SCH_2S$-, $-SCH_2O$-, or $-OCH_2S$-;

R^9 is

$R^{15}R^{16}NCO$-,

$R^{15}R^{16}NCS$-,

$R^{17}OCO$-,

$R^{15}CO$-, or

H;

R^{10} and R^{11} are independently H, H_2N-, or CH_3CONH-;

and pharmaceutically acceptable salts thereof.

Claim 12-15 (canceled).

Claim 16 (currently amended): A compound of Formula II:



wherein

R^1 and R^4 are independently

H,

HO,

$R^{13}O$-,

$R^{13}S$-,

halogen,

C1-C3-alkyl,

CF_3,

$R^{14}CO_2$-,

$R^{14}O_2C$-,

$R^{14}CO$-,

$R^{14}CONH$-,

$R^{14}NHCO$-,

$R^{14}NHCO_2$-,

$R^{14}OCONH$-,

$R^{14}O_2S$-,

$R^{14}OS$-, or

$R^{15}R^{16}N$-; or

R^2 is one of H, HO, $R^{13}O$-, halogen, C1-C3-alkyl, CF_3, $R^{14}CO_2$-, $R^{14}O_2C$-, $R^{14}CO$-, $R^{14}CONH$-, $R^{14}NHCO$-, $R^{14}NHCO_2$-, $R^{14}OCONH$-, $R^{14}O_2S$-, $R^{14}OS$-, $R^{13}S$- and $R^{15}R^{16}N$- when R^3 is one of HO, halogen, C1-C3-alkyl, CF_3, $R^{14}CO_2$-, $R^{14}O_2C$-, $R^{14}CO$-, $R^{14}CONH$-, $R^{14}NHCO$-, $R^{14}NHCO_2$-, $R^{14}OCONH$-, $R^{14}O_2S$-, $R^{14}OS$-, $R^{13}S$- and $R^{15}R^{16}N$-; or

R^2 is one of H, HO, halogen, C1-C3-alkyl, CF_3, $R^{14}CO_2$-, $R^{14}O_2C$-, $R^{14}CO$-, $R^{14}CONH$-, $R^{14}NHCO$-, $R^{14}NHCO_2$-, $R^{14}OCONH$-, $R^{14}O_2S$-, $R^{14}OS$-, $R^{13}S$- and $R^{15}R^{16}N$- when R^3 is one of H, HO, $R^{13}O$-, halogen, C1-C3-alkyl, CF_3, $R^{14}CO_2$-, $R^{14}O_2C$-, $R^{14}CO$-, $R^{14}CONH$-, $R^{14}NHCO$-, $R^{14}NHCO_2$-, $R^{14}OCONH$-, $R^{14}O_2S$-, $R^{14}OS$-, $R^{13}S$- and $R^{15}R^{16}N$-; or

R^1 and R^2, or R^2 and R^3, or R^3 and R^4 taken together can be

$-SCH_2S-$,

$-SCH_2O-$,

$-OCH_2S-$,

$-SCH_2CH_2S-$,

$-SCH_2CH_2O-$, or

$-OCH_2CH_2S-$;

wherein one of the substituents of R^1, R^3 and R^4 must be C1-C3-alkoxy or C1-C3-alkylthio group;

R^5, R^6 and R^7 are independently

H,

C1-C6-alkyl,

C3-C6-alkenyl,

C3-C6-cycloalkyl,

phenyl or substituted phenyl, wherein the phenyl is substituted with one or two substituents, C1-C3-alkyl, halogen, $R^{13}O-$, CF_3-, $R^{14}O_2S-$, $R^{14}OS-$, $R^{14}CO-$, $R^{14}CO_2-$, $R^{14}O_2C-$, $R^{14}CONH-$, $R^{14}NHCO-$; or

R^5 and R^6 taken together can be C3-C6-cycloalkyl;

R^{13} is C1-C3-alkyl;

R^{14} is H or C1-C3-alkyl;

R^{15} and R^{16} are independently

H,

C1-C10-alkyl,

C1-C6-perfluoroalkyl,

C3-C10-alkenyl, or

C3-C6-cycloalkyl; or

R^{15} and R^{16} taken together can be C3-C6-cycloalkyl;

R^{18} and R^{19} are independently

H,

halogen,

C1-C3-alkyl,

$R^{14}O$-,

CF_3-, or

$R^{14}CO_2$-;

R^{20} and R^{21} are independently

H,

$R^{15}R^{16}N$-,

$R^{15}HNC(NH)$- or

$R^{14}CONH$-;

and pharmaceutically acceptable salts thereof;

wherein R^{20} and R^{21} cannot both be H.

Claim 17 (previously presented): The compound of claim 16 of Formula II

wherein one of the substituents of R^1, R^3 and R^4 must be Cl—C3—alkylthio group or Cl—C3—alkoxy group, the other substituents are independently H, $R^{13}O$-, $R^{13}S$-, halogen, or C1-C3-alkyl;

R^2 and R^3 taken together can be $-SCH_2S-$, $-SCH_2O-$, or $-OCH_2S-$;

R^{20} and R^{21} are independently H, H_2N-, or CH_3CONH-;

and pharmaceutically acceptable salts thereof.

Claim 18 (previously presented): A composition comprising the compound of claim 17 and a pharmaceutically acceptable carrier.

Claims 19-22 (canceled).

Claim 23 (previously presented): A composition comprising the compound of claim 16 and a pharmaceutically acceptable carrier.

Claim 24 (canceled).

Claim 25 (currently amended): A method for treating a patient, the method comprising administering to the patient, in an effective amount to alleviate the symptoms of the ischemia, epilepsy or stroke, a compound of Formula II:



wherein

R^1 and R^4 are independently

H,

HO,

$R^{13}O$-,

$R^{13}S$-,

halogen,

C1-C3-alkyl,

CF_3,

$R^{14}CO_2$-,

$R^{14}O_2C$-,
$R^{14}CO$-,
$R^{14}CONH$-,
$R^{14}NHCO$-,
$R^{14}NHCO_2$-,
$R^{14}OCONH$-,
$R^{14}O_2S$-,
$R^{14}OS$-, or
$R^{15}R^{16}N$-; or

R^2 is one of H, HO, $R^{13}O$-, halogen, C1-C3-alkyl, CF_3, $R^{14}CO_2$-, $R^{14}O_2C$-, $R^{14}CO$-, $R^{14}CONH$-, $R^{14}NHCO$-, $R^{14}NHCO_2$-, $R^{14}OCONH$-, $R^{14}O_2S$-, $R^{14}OS$- and $R^{15}R^{16}N$- when R^3 is one of HO, halogen, C1-C3-alkyl, CF_3, $R^{14}CO_2$-, $R^{14}O_2C$-, $R^{14}CO$-, $R^{14}CONH$-, $R^{14}NHCO$-, $R^{14}NHCO_2$-, $R^{14}OCONH$-, $R^{14}O_2S$-, $R^{14}OS$-, $R^{13}S$- and $R^{15}R^{16}N$-; or

R^2 is one of H, HO, halogen, C1-C3-alkyl, CF_3, $R^{14}CO_2$-, $R^{14}O_2C$-, $R^{14}CO$-, $R^{14}CONH$-, $R^{14}NHCO$-, $R^{14}NHCO_2$-, $R^{14}OCONH$-, $R^{14}O_2S$-, $R^{14}OS$- and $R^{15}R^{16}N$- when R^3 is one of H, HO, $R^{13}O$-, halogen, C1-C3-alkyl, CF_3, $R^{14}CO_2$-, $R^{14}O_2C$-, $R^{14}CO$-, $R^{14}CONH$-, $R^{14}NHCO$-, $R^{14}NHCO_2$-, $R^{14}OCONH$-, $R^{14}O_2S$-, $R^{14}OS$-, $R^{13}S$- and $R^{15}R^{16}N$-; or

R^1 and R^2, or R^2 and R^3, or R^3 and R^4 taken together can be
$-SCH_2S$-,
$-SCH_2O$-,
$-OCH_2S$-,
$-SCH_2CH_2S$-,
$-SCH_2CH_2O$-, or
$-OCH_2CH_2S$-;

wherein one of the substituents of R^1, R^3 and R^4 must be C1-C3-alkoxy or C1-C3-alkylthio group;

R^5, R^6, and R^7 are independently

H,

C1-C6-alkyl,

C3-C6-alkenyl,

C3-C6-cycloalkyl,

phenyl or substituted phenyl, wherein the phenyl is substituted with one or two substituents, C1-C3-alkyl, halogen, $R^{13}O$-, CF_3-, $R^{14}O_2S$-, $R^{14}OS$-, $R^{14}CO$-, $R^{14}CO_2$-, $R^{14}O_2C$-, $R^{14}CONH$-, $R^{14}NHCO$-; or

R^5 and R^6 taken together can be C3-C6-cycloalkyl;

R^{13} is C1-C3-alkyl;

R^{14} is H or C1-C3-alkyl;

R^{15} and R^{16} are independently

H,

C1-C10-alkyl,

C1-C6-perfluoroalkyl,

C3-C10-alkenyl, or

C3-C6-cycloalkyl; or

R^{15} and R^{16} taken together can be C3-C6-cycloalkyl;

R^{18} and R^{19} are independently

H,

halogen,

C1-C3-alkyl,

$R^{14}O$-,

CF_3-, or

$R^{14}CO_2$-;

R^{20} and R^{21} are independently

H,

$R^{15}R^{16}N$-,

$R^{15}HNC(NH)$- or

$R^{14}CONH$-;

and pharmaceutically acceptable salts thereof;

wherein R^{20} and R^{21} cannot both be H[.]

in combination with a pharmaceutically acceptable carrier.

Claim 26 (previously presented): The method of claim 25 wherein, in the compound of Formula II

wherein one of the substituents of R^1, R^3 and R^4 must be Cl—C3—alkylthio group or Cl—C3—alkoxy group, the other substituents are independently H, $R^{13}O$-, $R^{13}S$-, halogen, or C1-C3-alkyl;

R_2 and R_3 taken together can be $-SCH_2S-$, $-SCH_2O-$, or $-OCH_2S-$;

R^{20} and R^{21} are independently H, H_2N-, or CH_3CONH-;

and pharmaceutically acceptable salts thereof.

Claims 27-30 (canceled).